#USA #Chicago #TuHURA Biosciences #KVA12123 #IFx-Hu2.0

TuHURA Biosciences at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc., a company advancing treatments in Phase 3 immune-oncology, will showcase its innovative research at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting. Scheduled from April 25 to April 30, 2025, at the McCormick Place Convention Center in Chicago, Illinois, this prestigious event will host significant discussions and presentations concerning advancements in cancer treatment.

This year, TuHURA has had two abstracts selected for poster presentations, underscoring its commitment to developing novel therapies aimed at overcoming resistance to cancer immunotherapy, a critical challenge in oncology. The meeting is an essential platform for sharing new ideas, fostering collaborations, and discussing the latest research findings in cancer treatment.

Abstract Highlights

1. Title: Initial results from a first-in-human phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Dr. Thierry Guillaudeux, Chief Scientific Officer at Kineta Inc.
Date and Time: April 28, 2025, from 9:00 AM to 12:00 PM ET
Location: Section 29
Abstract Number: CT041/20
In this study, the novel KVA12123 antibody, an anti-VISTA therapy, is analyzed both in isolation and alongside pembrolizumab, a well-known anti-PD-1 treatment. This approach aims to provide insights into the efficacy of combining therapies to improve outcomes for patients with advanced malignancies.

2. Title: Mechanistic insights into IFx-Hu2.0 responses in the first human trial after prior anti-PD-1 therapy failure
Presenter: Dr. Joseph Markowitz
Date and Time: April 28, 2025, from 2:00 PM to 5:00 PM ET
Location: Section 35
Abstract Number: 3428/23
This presentation will delve into how TuHURA's innovative IFx-Hu2.0 therapy functions, especially in patients who did not respond adequately to previous anti-PD-1 treatments. The exploration of these mechanisms represents a vital step in refining therapeutic strategies for patients suffering from advanced melanoma.

These presentations reflect TuHURA's ongoing efforts to develop treatments that address the challenges of immune resistance in cancer therapies. With the anticipated completion of its merger with Kineta Inc., TuHURA is poised to enhance its research and development capabilities, particularly through the potential integration of Kineta's KVA12123 antibody.

TuHURA's Commitment to Innovation

As a Phase 3 immuno-oncology company, TuHURA specializes in creating technologies that aim to combat both primary and acquired resistance to existing cancer immunotherapies. The company's primary product candidate, IFx-2.0, seeks to mitigate the initial resistance to checkpoint inhibitors, a common hurdle in cancer treatment efficacy.

Looking ahead, TuHURA plans to initiate a randomized, placebo-controlled Phase 3 registration trial for IFx-2.0 as an adjunctive therapy to Keytruda® in treating advanced or metastatic Merkel Cell Carcinoma. This study represents an important milestone in evaluating how TuHURA’s products can work in conjunction with established therapies to enhance patient outcomes.

Moreover, TuHURA is actively leveraging Delta Opioid Receptor technology to develop first-in-class bi-specific antibody drug conjugates, aiming to tackle the immune-suppressing effects present in tumor microenvironments. By inhibiting these effects, TuHURA intends to prevent T cell exhaustion and bolster the overall response to therapies.

For further details about TuHURA and its upcoming presentations at the AACR, stakeholders and interested parties can visit TuHURA’s website for the latest updates and information.

As TuHURA prepares for this important event, it also emphasizes the need for collaboration, community engagement, and information sharing in the pursuit of progress against cancer. The company invites all attendees at AACR 2025 to engage with its research and to be part of the conversation surrounding innovative cancer therapies and patient care.

Conclusion

The AACR Annual Meeting is not just a venue for presenting research but a gathering that promotes interaction among scientists, physicians, and industry leaders. TuHURA’s presentations will contribute valuable data toward understanding cancer treatment responses and advancing the field of immuno-oncology. With the spirit of innovation at the forefront, TuHURA continues to make strides toward a future where cancer therapies can be more effective and accessible to patients worldwide.